WHD this week finalized its acquisition of a 65% equity interest in Baker Hughes’ Surface Pressure Control (SPC) business, creating a joint venture valued at approximately $300 million. The transaction, announced on January 5 and closed within 60 days, grants WHD control over production, R&D and global distribution for a product line that generated $220 million in revenue during the last fiscal year. Management expects annual cost synergies of $12 million by 2027 through combined procurement, streamlined manufacturing and consolidated field service operations across North America, Europe and the Middle East.

By integrating Baker Hughes’ SPC assets—namely high-pressure valves, chokes and related control systems—WHD will boost its addressable market by an estimated 35%, extending its customer network into over 40 countries. The joint venture anticipates onboarding 120 skilled technicians from the SPC unit, increasing WHD’s global field force by 18%. Executives forecast that the enlarged footprint will support a mid‐teens compound annual growth rate for pressure control products through 2028, driven by rising deepwater and unconventional well activity in South America and West Africa.

Following the deal’s completion, WHD shares climbed 5.7% in yesterday’s session on trading volume of 1.2 million shares, roughly 50% above the 90‐day daily average. Despite the uptick, consensus earnings‐per‐share forecasts have been trimmed by 2.3% over the past month, reflecting concerns about margin pressure from raw‐material inflation and integration costs estimated at $8 million in the first year. Of 12 analysts covering WHD, four have raised their price targets since the announcement, while three have lowered theirs, resulting in a neutral consensus rating.

WHD’s management reiterated its 2026 guidance range for adjusted EBITDA of $140 million to $150 million, now including contributions from the SPC joint venture. Capital expenditures are expected to rise by $20 million this year as WHD invests in two upgraded machining facilities and expands its automated testing lab in Houston. Investors will be monitoring the joint venture’s first‐quarter integration milestones, particularly the successful launch of a new choke product line in April, which could unlock incremental free cash flow and validate the strategic rationale for the deal.